Clinical ResearchInterventional CardiologyIntracoronary Enalaprilat to Reduce Microvascular Damage During Percutaneous Coronary Intervention (ProMicro) Study
Interventional Cardiology
Under an Elsevier user license
open archive
Key Words
angiotensin-converting enzyme inhibitors
coronary artery disease
coronary intervention
coronary microvascular function
Abbreviations and Acronyms
ACE
angiotensin-converting enzyme
CFR
coronary flow reserve
FFR
fractional flow reserve
hs-cTnT
high-sensitivity cardiac troponin T
IMR
index of microvascular resistance
PCI
percutaneous coronary intervention
PMI
periprocedural myocardial infarction
Cited by (0)
Dr. Wijns has relationships with Ablynx, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Therabel, Abbott Vascular, Biotronik, Boston Scientific, Cordis J&J, Edwards, Medtronic, Orbus Neich, St. Jude, and Terumo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.